Goldman J, Pfister D, Vukmirovich R
Mol Cell Endocrinol. 1987 Apr;50(3):183-91. doi: 10.1016/0303-7207(87)90016-5.
Kallikrein and bradykinin additively increased adipocyte hexose transport under conditions of maximal intrinsic insulin stimulation, while no such effect occurred in the absence of insulin. The potentiation of insulin action follows a dose-response relationship with kallikrein and bradykinin concentrations consistent with a physiological role for the latter in the modulation of insulin action. Insulin degradation by isolated adipocytes and insulin binding to its receptors on adipocyte plasma membranes were not affected by either kallikrein or bradykinin. Thus, the kallikrein and bradykinin potentiation of insulin action occur at post-insulin binding sites. In conclusion, the kallikrein-bradykinin system increases the supply of substrates to target tissues through vasodilation and augmented blood perfusion, and it also stimulates glucose uptake and metabolism via its potentiation of insulin action. These actions suggest that the kallikrein-bradykinin system regulate both the availability and utilization of metabolic substrates, in target tissues.
在最大程度的内源性胰岛素刺激条件下,激肽释放酶和缓激肽可相加性地增加脂肪细胞己糖转运,而在无胰岛素的情况下则无此效应。胰岛素作用的增强与激肽释放酶和缓激肽浓度呈剂量反应关系,这与后者在调节胰岛素作用中的生理作用一致。分离的脂肪细胞对胰岛素的降解以及胰岛素与其在脂肪细胞质膜上的受体的结合均不受激肽释放酶或缓激肽的影响。因此,激肽释放酶和缓激肽对胰岛素作用的增强发生在胰岛素结合后位点。总之,激肽释放酶-缓激肽系统通过血管舒张和增强血液灌注增加底物向靶组织的供应,并且它还通过增强胰岛素作用来刺激葡萄糖摄取和代谢。这些作用表明激肽释放酶-缓激肽系统调节靶组织中代谢底物的可用性和利用。